Gioia Colafigli

739 total citations
41 papers, 333 citations indexed

About

Gioia Colafigli is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Gioia Colafigli has authored 41 papers receiving a total of 333 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Hematology, 29 papers in Genetics and 13 papers in Rheumatology. Recurrent topics in Gioia Colafigli's work include Chronic Myeloid Leukemia Treatments (27 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Acute Myeloid Leukemia Research (16 papers). Gioia Colafigli is often cited by papers focused on Chronic Myeloid Leukemia Treatments (27 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Acute Myeloid Leukemia Research (16 papers). Gioia Colafigli collaborates with scholars based in Italy, United States and Netherlands. Gioia Colafigli's co-authors include Massimo Breccia, Emilia Scalzulli, Robin Foà, Matteo Molica, Roberto Latagliata, Sara Pepe, Giuliana Alimena, Fulvio Massaro, Maurizio Martelli and Daniela Diverio and has published in prestigious journals such as Blood, Oncotarget and Critical Reviews in Oncology/Hematology.

In The Last Decade

Gioia Colafigli

38 papers receiving 329 citations

Peers

Gioia Colafigli

HEMAT

GENET

RHEUM

ONCOL

Sara Vieira Portugal

Valentina Giai Italy

Federico Vozella Italy

Daigo Akahane Japan

R. Hehlmann Germany

Christos Poziopoulos Greece

Caterina Stefanizzi Italy

Elisa Zuffa Italy

Audrey Bidet France

Pedro Enrique Dorlhiac Llacer Brazil

Sara Vieira Portugal

Gioia Colafigli

164 ×0.6

HEMAT

106 ×0.6

GENET

112 ×1.1

55 ×0.9

RHEUM

50 ×0.9

ONCOL

Citations per year, relative to Gioia Colafigli Gioia Colafigli (= 1×) peers Sara Vieira

Countries citing papers authored by Gioia Colafigli

Since Specialization

Citations

This map shows the geographic impact of Gioia Colafigli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gioia Colafigli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gioia Colafigli more than expected).

Fields of papers citing papers by Gioia Colafigli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gioia Colafigli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gioia Colafigli. The network helps show where Gioia Colafigli may publish in the future.

Co-authorship network of co-authors of Gioia Colafigli

This figure shows the co-authorship network connecting the top 25 collaborators of Gioia Colafigli. A scholar is included among the top collaborators of Gioia Colafigli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gioia Colafigli. Gioia Colafigli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Scalzulli, Emilia, Giovanni Caocci, Fabio Efficace, et al.. (2021). Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients. Annals of Hematology. 100(5). 1213–1219. 3 indexed citations

Breccia, Massimo, et al.. (2021). Measuring prognosis in chronic myeloid leukemia: what’s new?. Expert Review of Hematology. 14(6). 577–585. 2 indexed citations

Scalzulli, Emilia, Gioia Colafigli, Roberto Latagliata, et al.. (2020). Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients. Annals of Hematology. 99(12). 2773–2777. 3 indexed citations

Colafigli, Gioia, Emilia Scalzulli, Sara Pepe, et al.. (2020). Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?. Critical Reviews in Oncology/Hematology. 157. 103163–103163. 13 indexed citations

Breccia, Massimo, Fabio Efficace, Gioia Colafigli, et al.. (2020). Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice. Expert Review of Hematology. 13(12). 1311–1318. 7 indexed citations

Scalzulli, Emilia, Gioia Colafigli, Sara Pepe, et al.. (2020). Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up. Leukemia & lymphoma. 62(4). 1026–1027. 3 indexed citations

Carmosino, Ida, Massimo Breccia, Sara Mohamed, et al.. (2019). Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib. Oncology Research and Treatment. 42(12). 660–664. 3 indexed citations

Scalzulli, Emilia, Matteo Molica, Danilo Alunni Fegatelli, et al.. (2019). Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice. Annals of Hematology. 98(8). 1919–1925. 6 indexed citations

Latagliata, Roberto, Massimo Breccia, Ida Carmosino, et al.. (2018). Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?. European Journal Of Haematology. 101(5). 578–584. 1 indexed citations

10.

Molica, Matteo, Emilia Scalzulli, Gioia Colafigli, et al.. (2018). Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events. Annals of Hematology. 97(10). 1803–1808. 18 indexed citations

11.

Breccia, Massimo, Alessandro Andriani, Marco Montanaro, et al.. (2016). Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN. Annals of Hematology. 96(3). 387–391. 13 indexed citations

12.

Mauro, Francesca Romana, Adriano Salaroli, Maria Caputo, et al.. (2016). Management of elderly and unfit patients with chronic lymphocytic leukemia. Expert Review of Hematology. 9(12). 1165–1175. 4 indexed citations

13.

Breccia, Massimo, Matteo Molica, Gioia Colafigli, Fulvio Massaro, & Giuliana Alimena. (2016). Early molecular response in chronic myeloid leukemia and halving time: Latest evidences. Leukemia Research. 48. 20–25. 9 indexed citations

14.

Breccia, Massimo, Eleonora Arboscello, Gioia Colafigli, et al.. (2016). Proposal for a tailored stratification at baseline and monitoring of cardiovascular effects during follow-up in chronic phase chronic myeloid leukemia patients treated with nilotinib frontline. Critical Reviews in Oncology/Hematology. 107. 190–198. 10 indexed citations

15.

Breccia, Massimo, Gioia Colafigli, Matteo Molica, & Giuliana Alimena. (2016). Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Expert Opinion on Drug Safety. 15(4). 525–533. 10 indexed citations

16.

Breccia, Massimo, Caterina Stefanizzi, Sara Raponi, et al.. (2014). Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocitic leukemia cells. Annals of Hematology. 93(11). 1819–1823. 15 indexed citations

17.

Breccia, Massimo, Clara Minotti, Ida Carmosino, et al.. (2014). Acute promyelocytic leukemia in patients aged >70 years: the cure beyond the age. Annals of Hematology. 94(2). 195–200. 10 indexed citations

18.

Breccia, Massimo, Maria Stefania De Propris, Clara Minotti, et al.. (2013). Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients. Leukemia Research. 38(2). 194–197. 18 indexed citations

19.

Breccia, Massimo, Giuseppina Loglisci, Vincenzo Federico, et al.. (2012). Deferasirox treatment for myelodysplastic syndromes: “real-life” efficacy and safety in a single-institution patient population. Annals of Hematology. 91(9). 1345–1349. 24 indexed citations

20.

Angelis, Federico De, Alice Di Rocco, Clara Minotti, et al.. (2012). Atypical presentation of anaplastic large T-cell lymphoma mimicking an articular relapse of rheumatoid arthritis in a patient treated with etanercept. A case report and literature review. Leukemia Research. 36(9). e199–e201. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact